Teva Industries, Ltd. has received the FDA approval for its AirDuo Digihaler, a combination of fluticasone propionate 113 mcg and salmeterol 14 mcg. This combination therapy digital inhaler is connected to a mobile app, providing information on inhaler use to patients with asthma.
AirDuo Digihaler is indicated for asthma treatment in patients above 12 years of age. Please note that this system is not a rescue inhaler.
The Digihaler helps patients to track how regularly and frequently they have been using their inhalers. This could help doctors and patients about the adherence of treatment and correct technique of using the inhalers.
The product contains in-built sensors that detect and measure inspiratory flow rates. The information is then sent to the user’s mobile app, allowing them to review their data and share it with their doctors.
AirDuo Digihaler combines a breath-actuated, multi-dose dry powder inhaler containing fluticasone propionate and salmeterol. Fluticasone is an inhaled corticosteroid medicine that decreases inflammation in the lungs. Salmeterol is a long-acting beta2 adrenergic agonist that relaxes the muscles in the airways.
The drugs were was approved in low, medium, and high doses, administered as one inhalation twice a day.
AirDuo Digihaler is expected to be available to patients under a prescription in 2020. Common side effects associated with AirDuo include oral thrush, back pain, headache, cough, and nasopharyngitis.
